Cargando…
CNS relapse of diffuse large B cell Lymphoma A single centre experience
BACKGROUND AND OBJECTIVE: Central nervous system (CNS) relapse of diffuse large B cell lymphoma (DLBCL) is relatively uncommon and nearly fatal. Two years CNS relapse risk is 0.8% in low, 3.9% in intermediate and 12% in high risk patients. Our aim was to study, the baseline characteristics and outco...
Autores principales: | Nazir, Adil, Fawad, Siddique, Neelam, Hameed, Abdul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Professional Medical Publications
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768843/ https://www.ncbi.nlm.nih.gov/pubmed/29492077 http://dx.doi.org/10.12669/pjms.336.13812 |
Ejemplares similares
-
Outcomes of first line chemotherapy in patients with chronic lymphocytic leukemia
por: Nazir, Adil, et al.
Publicado: (2016) -
MicroRNAs as predictors for CNS relapse of systemic diffuse large B-cell lymphoma
por: Pillar, Nir, et al.
Publicado: (2017) -
PB2334: CENTRAL NERVOUS SYSTEM (CNS) RELAPSE IN DIFFUSE LARGE B-CELL LYMPHOMA: CNS-SAMATYA RISK MODEL
por: Yokus, Osman, et al.
Publicado: (2023) -
High-dose methotrexate is effective for prevention of isolated CNS relapse in diffuse large B cell lymphoma
por: Ong, Shin Yeu, et al.
Publicado: (2021) -
Systemic Relapse in a Young Adult Patient with Primary CNS Diffuse Large B-Cell Lymphoma
por: Khorasanchi, Adam, et al.
Publicado: (2022)